RTP Mobile Logo

Friday, December 8, 2017, Atlanta, Georgia, 12:30 PM – 3:30 PM (Eastern Time)

Addressing Current Questions and Controversies in the Management of Lymphoma and Chronic Lymphocytic Leukemia (Part 1 of a 2-Part Series)

A Friday Satellite Symposia Series Preceding the 59th ASH Annual Meeting

Event Details

Atlanta Marriott Marquis
265 Peachtree Center Avenue
Atlanta, GA 30303
Hotel Phone: 404-521-0000

Event Times:
12:30 PM – 1:00 PM (Eastern Time) — Registration and Lunch Buffet
1:00 PM – 3:30 PM (Eastern Time) — Educational Meeting

Meeting Room:
Marquis Ballroom B-D (Marquis Level)

There is no registration fee for this event. However, preregistration is advised, as seating is limited.

Craig Moskowitz, MD
Stephen A Greenberg Chair in Lymphoma Research
Clinical Director, Division of Hematologic Oncology
Attending Physician
Lymphoma and Adult BMT Services
Member, Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Medical College of Cornell University
New York, New York

Jonathan W Friedberg, MD, MMSc
Samuel E Durand Professor of Medicine
Director, James P Wilmot Cancer Institute
University of Rochester
Rochester, New York

Martin Dreyling, MD, PhD
Professor of Medicine
Department of Medicine III
University Hospital – LMU Munich
Munich, Germany

Owen A O’Connor, MD, PhD
Professor of Medicine and
Developmental Therapeutics
Director, Center for Lymphoid Malignancies
Columbia University Medical Center
College of Physicians and Surgeons
NewYork-Presbyterian Hospital
New York, New York

Laurie H Sehn, MD, MPH
Centre for Lymphoid Cancer
BC Cancer Agency and
University of British Columbia
Vancouver, British Columbia, Canada

Neil Love, MD
Research To Practice
Miami, Florida


This activity, the first in a 2-part series, will focus on common practical issues and challenges encountered by clinicians caring for patients with lymphoma and chronic lymphocytic leukemia (CLL). Prior to the event, Research To Practice will consult with 5 community-based medical and hematologic oncologists to identify specific clinical situations or questions for which they would seek investigator input. The meeting will feature a faculty panel of 5 renowned investigators and will be divided into 5 modules, each focused on a distinct lymphoma variant or CLL. Each module will include a discussion of the questions and issues presented by the consulting oncologists and a faculty member-led review of relevant ongoing research. Clinicians in attendance will use networked iPads® to participate in a premeeting survey related to the topics and questions to be discussed. Polling results will be interspersed throughout each discussion to elucidate any knowledge and practice gaps that may exist within the community. A full agenda will be made available in the fall.

CE Information

Target Audience:
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphoma and chronic lymphocytic leukemia (CLL).

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Individualize the selection and sequence of systemic therapy for patients with newly diagnosed and relapsed/refractory (R/R) CLL, considering the patient’s clinical presentation, biomarker profile and psychosocial status.
  • Consider existing and emerging clinical research data in the formulation of therapeutic recommendations for patients with newly diagnosed and R/R diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma.
  • Incorporate new therapeutic strategies into the best-practice management of newly diagnosed and R/R Hodgkin lymphoma (HL).
  • Assess the benefits and risks of evidence-based systemic treatment options to individualize and optimize the care of patients with T-cell lymphoma.
  • Compare and contrast the mechanisms of action, efficacy and safety of approved and investigational immune checkpoint inhibitors for the treatment of HL and non-Hodgkin lymphoma (NHL) to determine the current and/or potential utility of each in clinical practice.
  • Develop an understanding of the biologic rationale for and early efficacy and toxicity data with the use of chimeric antigen receptor (CAR)-directed T-cell therapy, and, where appropriate, facilitate access to ongoing trials of this investigational approach for patients diagnosed with select B-cell lymphomas and CLL.
  • Assess the ongoing clinical trials evaluating other novel investigational approaches for HL, NHL and CLL, and obtain consent from appropriate patients for study participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP/Acerta Pharma, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics and Takeda Oncology.


Atlanta Marriott Marquis
265 Peachtree Center Avenue
Atlanta, GA 30303
Hotel Phone: 404-521-0000

Meeting Room:
Marquis Ballroom B-D (Marquis Level)

The Atlanta Marriott Marquis Hotel is conveniently located within 1 mile of the Georgia World Congress Center where the ASH Annual Meeting is taking place.



This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of Hodgkin and non-Hodgkin lymphoma, including chronic lymphocytic leukemia.

There is no registration fee for this event. However, preregistration is advised, as seating is limited.

Registration for clinicians in practice

I am a practicing physician, fellow or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/ industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least one half hour prior to the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.